Back to Journals » Clinical Ophthalmology » Volume 10

Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials

Authors Oellers P, Grewal D, Fekrat S

Received 21 October 2015

Accepted for publication 14 January 2016

Published 8 March 2016 Volume 2016:10 Pages 411—418


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Patrick Oellers,1,2 Dilraj S Grewal,1,2 Sharon Fekrat1,2

1Duke Eye Center, Duke University Medical Center, 2Surgical Service, Durham Veterans Affairs Medical Center, Durham, NC, USA

Abstract: For years, the standard of care for branch-retinal-vein-occlusion-associated macular edema was initial observation followed by grid-pattern laser photocoagulation for persistent edema. Newer pharmacologic options have revolutionized the management of branch-retinal-vein-occlusion-associated macular edema, and the visual outcomes of these eyes are better than ever. However, a variety of available treatment options including intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents have established novel challenges with regard to appropriate drug selection. This review summarizes the available clinical studies with special emphasis on the comparison of intravitreal aflibercept with ranibizumab, bevacizumab, and steroid agents.

Keywords: branch retinal vein occlusion, BRVO, macular edema, cystoid macular edema, grid-pattern laser photocoagulation, triamcinolone, dexamethasone implant, ranibizumab, bevacizumab, pegaptanib, anti-vascular endothelial growth factor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]